In patients with hypertension and diabetic nephropathy, it has recently been suggested that combination treatment comprising an RAS inhibitor plus an MR blocker can further improve renal outcomes compared with the effects of an RAS inhibitor alone [14]. The gene discussed is NR3C2; the disease is hypertensive disorder.